CASE PRESENTATION
A 28-year-old Cambodian man with complex congenital heart disease presented with a 6-month history of increasing fatigue, night sweats, and an unintentional 30-pound weight loss. The patient reported a history of congenital heart disease, including two BlalockTaussig shunts placed 9 years of age and a subsequent surgical ventricular septal defect closure and placement of a pulmonary valve conduit via a Rastelli procedure. He denied illicit drug use and was on no medications. The physical exam was significant for a grade IV/VI holosystolic murmur, heard loudest at the right upper sternal border and a grade III/VI early diastolic murmur at the right upper sternal border.
Transthoracic echocardiography (TTE) and subsequent cardiac computed tomographic angiography revealed mesocardia, situs solitus, L-loop ventricle, and a Rastelli-type pulmonary valve conduit ( Figure 1) . A 1.8 Â 1.1 cm mobile echodensity was seen attached to the distal portion of the pulmonary homograft and was associated with increased systolic flow with peak velocity of 3 m/s and severe regurgitation on TTE. Transesophageal echocardiography and cardiac computed tomographic angiography demonstrated the previously seen mobile density as well as additional smaller echodensities attached the wall of the homograft (Figure 2 , Videos 1 and 2). Given the patient's symptoms, these findings were concerning for vegetations. The systemic (anatomic right) ventricle was moderately dilated with moderate systolic dysfunction, with an ejection fraction of 38.7%. The pulmonary (anatomic left) ventricle was mildly dilated with normal systolic function (ejection fraction, 55%). Also seen were moderate aortic regurgitation, mild pulmonary atrioventricular valve (mitral) regurgitation, mild to moderate systemic atrioventricular (tricuspid) regurgitation, and the prior ventricular septal defect repair with no residual leak. Four of four blood cultures grew gramnegative rods, later identified as Suttonella indologenes, susceptible to ampicillin and ceftriaxone. The patient received a 6-week course of intravenous ceftriaxone 2 g/day through a peripherally inserted central catheter, followed by a 12-week course of oral amoxicillin 875 mg twice a day. The patient was deemed at high risk for surgical intervention because of prior cardiac surgeries and was discharged upon improvement in his constitutional symptoms.
Ten days after discharge, the patient returned to the emergency room complaining of sudden onset of pleuritic right-sided chest pain. Computed tomography of the chest revealed a pulmonary embolism in the right lower lobe (Figure 3 ). An ultrasound of the peripherally inserted central catheter line site showed no evidence of thrombosis. Repeat TTE demonstrated a marked decrease in the size of the mobile density in the pulmonary homograft, consistent with embolization of homograft vegetation. Repeat blood cultures were negative. The patient's symptoms improved, and he was discharged home on hospital day 3. The patient is doing well 21 months after discharge and remains in New York Heart Association class I.
DISCUSSION
This is the first known case of echocardiographically documented prosthetic endocarditis caused by S. indologenes. The same bacterium under prior classification, Kingella indologenes, 1 was reported in a patient with a history of mitral and aortic valve replacements and positive blood cultures, but without vegetations seen on TTE and M-mode imaging. 2 Although S. indologenes is not officially part of the HACEK group (Haemophilus parainfluenzae, H. aphrophilus, H. paraphrophilus, H. influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae, and K. denitrificans), it is considered to be part of the Cardiobacteriaceae family, with similar 16S ribosomal ribonucleic acid sequences as C. hominis.
1
Infective endocarditis (IE) caused by fastidious gram-negative bacilli of the HACEK group is responsible for about 5% to 10% of native valve community-acquired endocarditis in nonusers of intravenous drugs. In the congenital heart disease population, the incidence of IE is not well documented on a wide scale, although it accounted for 4% of admissions to a specialized adult congenital heart unit, as observed by Li and Somerville, 3 with Streptococcus viridans being the most common infective organism. Epidemiologic studies of IE have reported congenital heart disease patients to constitute 11% to 13% of cases. 4 An Oregon registry of patients with surgically corrected congenital heart defects classified corrected pulmonary atresia as ''high'' annual risk for IE, with 6.4 cases per 1,000 patient-years. Overall, there was a 10-year cumulative incidence of 5.3% in patients with histories of pulmonary atresia combined with an intact ventricular septum and 6.4% combined with a ventricular septal defect. 5 A retrospective review done by Di Filippo et al. 6 at their institution comparing characteristics of 153 cases of IE in patients with congenital heart disease before and after 1990 saw an increase in IE in Rastelli correction cases after 1990 (27.8% vs 4.8%).
The American Heart Association guidelines currently recommend treatment with ceftriaxone, ampicillin-sulbactam, or ciprofloxacin intravenously for 4 weeks in HACEK native valve endocarditis and for 6 weeks in prosthetic valve endocarditis. Because of the rise of b-lactamase-producing strains of HACEK, they are often ampicillin resistant. Virtually all strains are susceptible to ceftriaxone or other third-generation or fourth-generation cephalosporins. 
